South African regulators have determined that Vertex Pharmaceuticals has adequately provided access to its cystic fibrosis medications, resolving a controversy over treatment costs. Patient activists are unhappy with the decision, arguing that the arrangement is unfair and will result in some patients continuing to suffer and die. This issue began when families and activists petitioned several governments to allow access to lower-cost, generic versions of Trikafta, a highly effective treatment for cystic fibrosis. Patients and their supporters have been advocating for increased access to Vertex medicines, leading to conflicts with governments. The situation has escalated to high-profile battles, such as in the U.K.
Source link
South African regulator decides Vertex provides sufficient access to CF drugs
